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 RÉSUMÉ 
  
 Le Costimulateur Inductible (ICOS) est un récepteur exprimé à la 
surface des cellules T CD4 auxiliaires et T CD8 cytotoxiques. Il fut démontré 
à l’aide de modèles murins de transplantation de moelle osseuse que 
ICOS joue un rôle important dans l’induction de la maladie du greffon 
contre l’hôte aigüe (GVHD). ICOS potentialise deux signaux médiés par le 
récepteur de cellules T (TCR) : l’activation de la phosphoinositide 3-kinase 
(PI3K) ainsi que la mobilisation interne de calcium. En conditions in vitro, 
dans les cellules CD4 et CD8, ICOS réussi à potentialiser le flux de calcium 
médié par le TCR indépendamment de PI3K. La voie de signalisation de 
ICOS impliquée dans la GVHD demeure inconnue. Cependant, en 
utilisant une lignée de souris ‘knock-in’ nommée ICOS-Y181F, dans laquelle 
le cellules T ont sélectivement perdu la capacité d’activer PI3K par 
l’entremise d’ICOS, nous avons démontré que les cellules T peuvent utiliser 
un mécanisme ICOS indépendant de PI3K afin d’induire la GVHD. 
  
 La mobilisation interne du Ca2+ mène à l’activation de NFAT, un 
facteur de transcription clé régulant des gènes comme IFN-γ, qui exprime 
une des cytokines clés impliquées dans la GVHD. Nous émettons comme 
hypothèse que la capacité pathogénique intacte des cellules T ICOS-
Y181F à induire la GVHD, repose sur la signalisation du Ca2+ indépendante 
de PI3K. Le but de mon projet est d’identifier les résidus responsables de 
cette signalisation de Ca2+ médiée par ICOS ainsi que le mécanisme par 
lequel ce récepteur fonctionne. À l’aide de la mutagénèse dirigée, j’ai 
généré des mutants d’ICOS et j’ai analysé par cytométrie en flux leur 
capacité à activer le flux de Ca2+. J’ai ainsi identifié un groupe de lysine 
sur la queue cytoplasmique d’ICOS situé à proximité de la membrane 
comme étant essentiel à la fonction de potentialisation du flux de Ca2+. 
Je fournis également des preuves de l’implication de la kinase Lck, 
membre de la famille de kinases Src, dans la voie de signalisation de ICOS 
médiant la potentialisation du flux de Ca2+. Ainsi, ICOS s’associe à Lck et 
mène à une augmentation de l’activation de PLCγ1, la protéine 
effectrice clé causant la sortie de Ca2+ de la réserve intracellulaire. 
 
 En conclusion, notre étude permet de comprendre davantage une 
des voies de signalisation d’ICOS. L’influx de Ca2+ dans les cellules T 
implique la voie ICOS-Lck-PLCγ1. Une compréhension plus approfondie de 
cette voie de signalisation pourrait s’avérer bénéfique afin d’élaborer de 
nouvelles stratégies menant à la prévention de maladies reliées à ICOS, 
comme la GVHD. 
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ABSTRACT 
 
The Inducible Costimulator (ICOS) is a receptor expressed on 
activated CD4 helper and CD8 cytotoxic T cells. It was previously shown 
that ICOS plays an important role in inducing acute graft versus host 
disease (GVHD) in murine models of allogeneic bone marrow 
transplantation (BMT).  ICOS potentiates TCR-mediated phosphoinositide 
3-kinase (PI3K) activation and intracellular calcium mobilization. In both 
CD4+ and CD8+ T cells, ICOS can potentiate TCR-mediated calcium flux in 
a PI3K-independent manner in vitro. However, the ICOS signal 
transduction pathway involved in GVHD remains unknown. Using a knock-
in strain of mice (termed ICOS-Y181F) in which T cells have selectively lost 
the ability to activate PI3K, we have recently shown that T cells can utilize 
PI3K-independent ICOS signaling pathways to induce GVHD.  
 
The mobilization of intracellular Ca2+ leads to the activation of NFAT, 
a key transcription factor regulating genes such as IFN-γ, one of the key T 
cell cytokines involved in GVHD. Therefore, we hypothesize that the intact 
pathogenic capacity of ICOS-Y181F T cells to induce GVHD relies on ICOS-
dependent, PI3K-independent calcium signaling. My goal is to identify the 
residue(s) responsible for this ICOS-mediated Ca2+ signaling and find the 
mechanism by which the receptor achieves its function. Through site-
directed mutagenesis and flow cytometric analysis of calcium fluxing 
capacities of mutant ICOS proteins, I identified a membrane proximal 
cluster of lysine residues that is essential in inducing ICOS-mediated Ca2+ 
signaling. I also provide evidence for the involvement of the Src family 
kinase Lck in ICOS-mediated Ca2+signaling. ICOS associates with Lck 
molecules, leading to the activation of PLCγ1, the key effector protein 
causing the release of Ca2+ from the intracellular pool.  
 
Taken together, our study is beginning to unravel a complexity in 
ICOS signaling, and implicates the ICOS-Lck-PLCγ1 axis in T cell calcium 
signaling and potentially the induction of GVHD. Further understanding of 
this pathway could prove beneficial in designing new strategies to 
prevent ICOS-related diseases such as GVHD. 
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INTRODUCTION 
1.1 Signal transduction pathways in T cells 
1.1.1 General Overview 
The immune system’s main role in the body is to rid it of invading 
pathogens by mounting a protective immunity. It also serves to prevent 
harm to the host by inducing tolerance to self-tissues. T cells stand as key 
effectors in adaptive immune responses and calibration of their activities is 
a founding concept of the immune response1. T cells also play a large 
part in autoimmune diseases. To acquire specific effector functions, T cells 
must have their T cell receptor (TCR) engaged. This process requires the 
participation of multiple signals coming from the T cell environment. 
Understanding how the various T cell signals integrate to lead to 
appropriate functional outcome and dissecting the basis of T cell 
activation and regulation, can eventually help us to control infections and 
autoimmunity. 
 T cells only recognize foreign antigens that are displayed on the 
surface of the host’s own cells. These antigens are derived from 
components of pathogens that are processed inside the cells; e.g. viruses, 
intracellular bacteria or pathogen products in the extracellular 
environment internalized by endocytosis. T cell activation can be broken 
down in four different stages: cell adhesion, antigen-specific activation, 
costimulation, and cytokine production or cytotoxicity (signaling). 
Adhesion between T cells and antigen presenting cells (APC) requires 
molecules such as integrins and selectins and is essential in coupling the 
cells together before ensuing cellular activation takes place. APCs 
acquire antigens through internalization (by receptor-mediated 
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endocytosis or phagocytosis) or infection and process the antigen-
specific peptides. Next, they display the antigenic peptides on their 
surface in association with major histocompatibility complexes (MHCs) 
class I or class II molecules. These peptide-MHC molecules are to be 
recognized by T lymphocytes through their TCRs. The interaction between 
the MHC and TCR are not sufficient for full T cell responses, as TCR signal 
alone does not lead to sustained expansion and differentiation of T cells. 
To bolster the subsequent pathways, intercellular costimulatory signals are 
required. Costimulation promotes downstream signaling leading to 
proliferation, differentiation and survival of T cells. Cells involved in 
costimulatory signals need to communicate this way to determine if such 
course of actions goes through or terminates. Alongside perpetuating 
these T cell functions, costimulation can also mediate proinflammatory 
signals or generate immune tolerance in the periphery to avoid unwanted 
tissue damage due to staggeringly active proinflammatory effector 
signals2.  
 The T cell program of proliferation and differentiation following MHC 
peptide presentation by APCs is controlled by signaling events that mainly 
take place in immunological synapse. The immunological synapse consists 
of an assembly of supramolecular activation clusters (SMACs) forming a 
ring-like structure3. The central SMAC (cSMAC) is composed of the TCR 
and its associated kinases. It represents the pivotal location where TCR 
signaling events take place. The peripheral SMAC (pSMAC) is composed 
of integrins (like lymphocyte function-associated antigen 1(LFA-1)4) 
stabilizing the interaction between the T cell and the APC and increasing 
the T-cell sensitivity to the antigen5. And lastly, the distal SMAC (dSMAC) 
comprises the molecules excluded from the central signaling center, e.g. 
phosphatases like CD456. 
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 The first signaling molecules activated lead to a branched network 
of signaling cascades surrounding the TCR. A signaling balance exists in 
order to prevent activation of naïve T cells by self-antigens. The signal the 
cell receives must reach an established threshold in order for the cell to be 
activated. Such a strong signal can normally only occur from an 
interaction with an APC presenting a foreign antigen. However, 
autoimmune diseases ensue when a self-reactive T cells are erroneously 
activated. 
 In the recent years, knowledge of the molecules involved in early 
TCR signaling has improved greatly, due in part to advances in super-
resolution microscopy (reviewed7). Also several new approach combine 
different techniques together to create powerful tools allowing better 
understanding of the events of TCR signaling. Coupling of mass 
spectrometry and cytometry created mass cytometry (cyTOF)8 and a 
combination of imaging and flow cytometry saw the conception of 
Imaging flow cytometry9. These novel techniques now allow us to address 
molecular interactions in a dynamic manner. In the following sections, I will 
depict the events happening after the TCR is engaged and what key 
molecules are involved in that process (A schematic representation of 
TCR signaling events relevant to my project is in Figure 1.1, p.11). 
  
1.1.2 Src family kinases 
 Src family kinases (SFKs) are essential in providing the signals 
required for the survival of naïve T cells10. Regulation of SFK functions is 
central to the TCR signaling events. Since the TCR itself has no inherent 
enzymatic activity, it largely depends on the SFKs to trigger signaling after 
initial TCR engagement. SFKs are positively regulated by phosphorylation 
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of an activating tyrosine residue located in their catalytic domain. The 
activating tyrosine stabilizes an open conformation and promotes the full 
kinase activity of the molecule. The negative regulation happens by 
phosphorylation of an opposing tyrosine located in the carboxy-terminal 
domain. This negative phosphorylation is accomplished by the SRC kinase 
Csk11. This leads to a closed conformation of the kinase and an inhibition 
of its kinase activity12-14. Activation of SFKs is achieved by 
autophosphorylation and dephosphorylation is mediated by several 
phosphatases such as CD45 and PTPN2215, 16. 
 
1.1.3 Lck 
 Following TCR engagement, the SFK member lymphocyte-specific 
protein tyrosine kinase (Lck) is the first molecule that becomes activated. 
Lck binds to the cytoplasmic tail of the TCR co-receptors CD4 and CD817. 
The co-receptors target the delivery of Lck into close proximity with its 
target: the TCR CD3 ζ-chains and their immunoreceptor tyrosine-based 
activation motifs (ITAMs)18. In naïve T cells, Lck is constitutively active in 
order to stabilize basal levels of CD3 ζ-chains phosphorylation19.  
 Dynamic segregation of the signaling molecules is apparent as 
some transmembrane phosphatase like CD45 are forced out of the 
immunological synapse, enabling optimal downstream activation. The 
exclusion of CD45 could be either due to its larger size or the binding 
energy of the TCR-peptide-MHC interaction forcing it out20, 21. Abundance 
of Lck at the immunological synapse dictates the phosphorylation of 
subsequent targets: ITAMs, CD3 chains, and the ζ-chain associated 
protein kinase of 70 kDa (ZAP-70).  
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 Recent evidence suggests that clustering in the early events of TCR 
activation is regulated by the conformational states of Lck22. However, the 
level of phosphorylation of Lck is relatively unchanged before and after T 
cell stimulation. Lck molecules are ≈40 % constitutively active23. This 
suggests that the local concentration of Lck rather then their 
phosphorylation state is more likely to direct TCR triggering. 
 
1.1.4 Molecules downstream of Lck 
 Once Lck phosphorylates the Syk-family kinase Zap-70, the latter 
undergoes conformational changes as well24. This leads to the ensuing 
phosphorylation of its target molecule: the key adaptor molecule linker of 
activated T cells (LAT). Another molecule that is phosphorylated by ZAP-70 
that associates with LAT is SLP7625. SLP76 colocalizes and connects with 
PLCγ1 and ITK.   
 The main role of LAT is to colocalize signaling molecules; to form a 
signalosome. LAT gets phosphorylated on several residues. These 
phosphorylated residues act as docking sites for kinases and other 
adaptors. For example, Lat recruits PLCγ1 through its tyrosine 136. LAT 
assures propagation of the TCR-mediated signals in a tightly regulated 
manner. Indeed, LAT-deficiency in Jurkat cells leads to impediment of TCR 
signals26. Also, partial loss-of-function mutation of LAT (Tyr136Phe) accounts 
for LAT-signaling pathology as severe as a total loss of LAT27. The multiple 
phosphorylated sites of LAT eventually lead to the recruitment of 
downstream molecules and adaptors, which then branch to several 
different signaling pathways. One of the consequences of these signaling 
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pathways are the nuclear mobilization of key transcription factors crucial 
for gene expression responsible for T cell differentiation and function. 
 
1.1.5 Fyn 
 Fyn is another SFK crucial for TCR signaling 28. The vast majority of Fyn 
is not constitutively associated with other proteins. Biochemical and 
genetic evidence have shown a partial redundancy between Lck and 
Fyn29. Lck is has now been shown to induce Fyn activation30. Some studies 
have tried to show that in cell lines deficient for Lck, Fyn could replace the 
activity of Lck, but T cell activation was not sustainable31, 32. Fyn may in 
fact be rather more important for T cell anergy33, 34 and may indicate that 
Fyn does not necessarily act downstream of Lck in a given signaling 
pathway. 
 
1.1.6 Ras/Erk 
 The complex formed by PLCγ1 and SLP-76 is one that regulates Ras 
activation35. Ras is a small G protein central to numerous physiological 
conditions. In T cells, the Ras guanine exchange factor (RasGEF) RasGRP1 
is phosphorylated on its tyrosine 184 by diacylglycerol (DAG), a secondary 
messenger generated by PLCγ136. The RasGEFs Sos1 and Sos2 are 
constitutively associated with the adaptor Grb2. They are recruited to the 
membrane where they have basal RasGEF activity via Grb2/LAT 
interactions37. Sos proteins contain an allosteric Ras–GTP binding site.  
When that site is engaged, the RasGEF activity is greatly enhanced38. Ras-
GTP binding to Sos allows the engagement of a positive feedback loop 
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between the two proteins39, 40. When Ras becomes activated, it induces 
multiple downstream pathways, including the Raf/MEK/ERK kinase 
cascade driving both T cell development and their effector functions41, 42. 
The Raf/MEK/Erk pathway can also be activated in a LAT-independent 
manner. It forms a complex with DAPP1, PLCγ1 and PAK143. 
  
1.1.7 Lipid Rafts 
 Plasma membranes of several cell types contain microdomains 
enriched with cholesterol and sphingomyelin, called lipid rafts44. 
Sphingolipids allow ordered assembly beyond regular phospholipid bilayer. 
These rafts can be seen as organized platforms that mobilize in the plane 
of the plasma membrane. Their main function is to segregate molecules 
from one another45. Lipid rafts were initially discovered by their insolubility 
in non-ionic detergents as opposed to other areas of the plasma 
membrane46, 47. This facilitates their isolation from the rest of the 
membrane. In T cells, some molecules involved in TCR signaling are found 
in lipid rafts and disrupting these rafts can abrogate TCR signaling. 
Lipidation of Lck in its membrane anchoring N-terminal motif relocates the 
protein into lipid rafts48. Approximately 25-50% of total Lck molecules co-
purifies with detergent insoluble fractions during lipid raft isolation49. Fyn is 
another molecule shown to be active in lipid rafts50. Some proteins such as 
ZAP-70 and PLCγ151, 52 are only transiently recruited into the lipid rafts. For 
the past two decades, numerous studies have been reported on lipid rafts 
without achieving a full comprehension. Not all studies are in accordance 
with the existence of the lipid rafts as some have questioned the 
approach to identify them53, 54. It’s still up for debate regarding their true 
existence as well as their role in TCR signaling55. 
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1.1.8 Costimulatory receptors 
 T cell co-signaling receptors (a broader concept accommodating 
positive and negative aspects of costimulation) positively or negatively 
modulate signaling pathways induced by TCR triggering. Co-signals 
consist of co-stimulatory and co-inhibitory signals56, 57. The crosstalk 
between co-signaling receptors and their respective ligand takes place in 
the T-APC contact area including the immunological synapse, where they 
influence the T cells for activation or inhibition58. Co-signaling receptors 
are broadly divided into those belonging to the immunoglobulin (Ig) 
superfamily (IgSF), the tumor necrosis factor (TNF) superfamily (TNFSF), and 
signaling lymphocytic activation molecule (SLAM) family. This classification 
is based on their phenotypic and signaling features. The CD28 and CD80 
(B7-1)/CD86 (B7-2) costimulatory pathways represent prototypes of the Ig 
family of co-signaling receptors and ligands. The extended CD28 family 
includes CD28, CTLA-4, PD-1, ICOS, and BTLA.  
 
1.1.9 CD28 and its ligands B7-1/B7-2  
 CD28 has been characterized as a homodimeric costimulatory 
receptor for the TCR complex and is responsible for providing signals 
required for T cell activation. During the very early stages of T-cell 
activation, CD28 is expressed on T cells and is ligated by B7-1/B7-2, which 
are constitutively expressed on dendritic cells (DCs) and inducible in other 
APCs such as B cells and monocytes59-62. CD28 stimulation has been 
shown to increase IL-2 production, promote survival of activated T cells 
and prevent T cell anergy 63. The cytoplasmic tail of CD28 contains three 
signaling motif. The first motif contains an YMNM sequence. It serves as a 
binding site for the SH2-containg proteins (p85, GADS and Grb2). The 
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second motif contains a PRRP sequence. It interacts with the SH3 domain 
of Itk. The third motif contains a PYAP sequence. It associates with the SH3 
domain of Grb2, GADS, Lck, and filamin-A. The association of Grb2 to the 
motifs YMNM and PYAP is crucial for the recruitment of PKCθ and RASGRP 
to the immunological synapse and its ensuing activation64, 65. The B7-1/B7-
2/CD28 pathway decreases the threshold for T cell activation. 
Subsequently, this results in T cell proliferation, the upregulation of anti-
apoptotic proteins like Bcl-xL, and the increase of IL-2 production66-68.  
 In contrast, B7-1 and B7-2 also deliver a co-inhibitory signal to 
activated T cells through CTLA-4, the CD28 antagonist. The cytoplasmic 
tail of CTLA-4 contains the immunoreceptor tyrosine inhibitory motif (ITIM) 
recruiting SHP-1 and SHP-269, 70. CTLA-4 possesses a higher affinity to B7 
ligands and competes out CD28 for their binding leading to signal-
independent T cell suppression by sequestering the ligands from the APC 
surface71. Contrary to the CD28 pathway, the B7/CTLA-4 pathway 
increases the threshold to reduce T cell activation and ultimately 
terminate it. B7-1 and B7-2 are considered to deliver bidirectional signaling 
critical for the downregulation of T cell response and induction of T cell 
tolerance. 
 Once CD28 is engaged in TCR-mediated signaling, it is thought to 
bind to phosphatidylinositde-3 kinase (PI3K). CD28 brings PI3K to the 
membrane where it will generate phosphatidylinositol (3,4,5)-triphosphate 
(PIP3) and anchor proteins containing pleckstrin homology (PH) domains. 
The catalytic PI3K helps to convert phosphatidylinositol (4,5)-bisphosphate 
(PIP2) into PIP3. The excess of PIP3 is removed by phosphatase and tensin 
homolog (PTEN). PI3K is required to activate Akt, the regulator of many 
downstream targets. PI3K binding alone doesn’t account for all the CD28 
effects.  Indeed, recent data from knock-in mouse models show that it is 
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the PYAP motif that plays most important role in CD28-mediated 
costimulation whereas the contribution of YMNM motif is minimal72. 
Nuclear factors of activated T cells (NFAT), as well as Nuclear Factor 
KappaB (NFκB), play a crucial role in the regulation of gene transcription, 
a function triggered by CD28 stimulation, independently of PI3K. 
	  
Figure 1.1 Simplified overview of TCR signaling leading to activation of the Ca2+ signaling 
pathway. Once an MHC molecule presents an antigenic peptide and engages the TCR, 
signaling pathways are activated leading to effector functions of the cell. One of the 
downstream signaling events that are activated is the nuclear relocalization of NFAT that 
induces the transcription of several genes, e.g. IL-2 and IFN-Υ. During the recognition of 
antigens by TCR complexes Lck is delivered nearby through association with coreceptors 
(CD4/CD8) and phosphorylates its target molecules: ITAM motifs on CD3 ζ-chains. 
Phosphorylated ITAMS recruit ZAP-70 kinases that activate LAT/GADS/SLP-76 signalosomes. 
Phosphorylated LAT recruits PLCγ1. Activated PLCγ1 generates secondary messengers 
DAG and IP3; IP3 in turn leads to the activation of calcineurin and eventually the nuclear 
relocalization of NFAT. It has been unclear how ICOS achieves potentiation of TCR-
mediated Ca2+ flux and if the activation of PI3K is required in regulation of the 
downstream Ca2+ signaling pathway. 
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1.2 The Inducible Costimulator (ICOS) 
1.2.1 General Description 
 It has almost been 15 years since the Inducible Costimulator (ICOS) 
was discovered73-75. ICOS is a costimulatory receptor of the CD28 family of 
costimulatory receptors and was found to be selectively ‘induced’ on 
activated T cells, hence its given name. It was later discovered that it was 
expressed on T cells in the germinal centers76, 77. ICOS also displayed a 
structural similarity with the prototypical costimulatory receptor CD28. 
However, ICOS binds to its ligand B7-H2, but not other members of B7 
family proteins78. Costimulation of ICOS enhances mainly cytokine 
production but promotes proliferation minimally. Both mice and humans, 
ICOS-deficiency leads to reduced antibody production due to impaired 
germinal center reaction.  We and others have shown that this is due to its 
crucial role in the development of Tfh cells79.  
1.2.2 ICOS Structure 
 Structurally, ICOS is similar to CD28. Both are type I transmembrane 
glycoproteins. The amino acid sequence of ICOS is divided in three 
distinctive sections: a signal peptide, a single IgV-like domain, a 23 amino-
acid transmembrane region and a 35 amino-acid cytoplasmic tail80. The 
whole ICOS sequence is composed of numerous amino acid clusters that 
are conserved through evolution between species. The two conserved 
cysteine residues at position 42 and 109 within the Ig domain are 
supposed to stabilize the Ig fold by forming disulfide bonds. On the surface, 
ICOS assembles as a homodimeric receptor. A conserved cysteine residue 
at position 136 is predicted to help forming the disulfide bridge between 
the homodimeric chains. In mice, ICOS has an apparent relative 
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molecular mass of 47-57 kDa75, 81.  
 
 In mice and humans, the amino-acid sequence of ICOS shares 
closely to 40% of sequence similarity with CD2878, 80; a significant number 
as 26% amino-acid identity is found between CD28 and CTLA-482. The 
human and mouse amino-acid sequences of ICOS share approximately 
70% identity, which is comparable to identity between human and mouse 
CD28 (69%)78. The similarities of sequences between species imply that the 
mechanism of action for ICOS in both mice and humans should be 
conserved, indicating that studies in mouse models are likely reflecting 
what would happen in humans. 
 
1.2.3 ICOS signaling mechanisms and functions 
 ICOS is known to potentiate two TCR-mediated signaling pathways: 
the PI3K pathway83-85 and the Ca2+ pathway85, 86. While ICOS binds PI3K 
directly, the mechanism of Ca2+ mobilization by ICOS remains unclear. At 
first, it was assumed that ICOS-mediated Ca2+ potentiation was an indirect 
result of PI3K activity, as PI3K induces Ca2+ mobilization in T cells87, but our 
lab showed that this function was occurring in a PI3K-independent 
manner79. 
 Similar to CD28’s YMNM motif, the cytoplasmic tail of ICOS contains 
a YMFM motif. Once the tyrosine in the motif is phosphorylated, it can 
recruit the SH2 domain- containing PI3K regulatory subunits p85α and p50α, 
but not Grb283, 88. Compared to CD28, ICOS has a much more potent 
capacity to activate PI3K79, 85. This may be due to a competition for 
binding between PI3K and Grb2 for the p-Tyr motif that happens in CD28 
cytoplasmic tail does not occurring ICOS. ICOS augments T cell effector 
functions, but not through augmenting proliferation of naïve T cells. It is 
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rather through enhancement of Th1 and Th2 cytokine production89-91. 
ICOS also regulates humoral immune responses by enabling germinal 
center T cells to achieve cognate interaction with B cells, providing a 
signal leading to a germinal center reaction and consequently, antibody 
maturation79, 92, 93. In preactivated CD4 T cells, ICOS is constitutively bound 
to PI3K and ICOS ligation further increases PI3K recruitment94. Co-ligation 
of the TCR and ICOS gives rise to a maximal PI3K signaling. It was 
highlighted by imaging and biochemical studies that ICOS is in complex 
with TCR complexes, and ICOS may get recruited into the immunological 
synapses. This supports the view that ICOS probably functions in 
conjunction with the TCR75, 88, 95. Moreover, inactivation of the p110δ 
isoform of PI3K also leads to impaired humoral immunity, reduced 
generation of Tfh cells, and impaired germinal center reaction 96, 97. 
Therefore, ICOS-PI3K signaling axis play critical role to support generation 
of Tfh cells. 
 Although ICOS-mediated Ca2+ flux can take place independently 
of ICOS-mediated PI3K activation, the molecular mechanisms and its 
biological significance were not known at the beginning of this project 
(depicted in Figure 1.1, p.11).  
 
1.2.4 Regulation of Expression 
 ICOS is expressed at low levels on naïve T cells and is significantly 
upregulated after TCR and CD28 costimulation78, 80. Fyn and Erk can 
regulate ICOS expression at the transcriptional level after T cell 
activation98. Fyn activates calcineurin, which in turn dephosphorylates 
NFATc2 and induces its nuclear translocation99. In the nucleus, NFATc2 
and Erk bind independently to the Icos promoter and activate its 
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transcription.  
 
 ICOS is expressed on Tfh cells, Th1, Th2, Tregs, Th17 and unpolarized 
activated CD4 T cells (Th0)100. Recent studies have shown that ICOS is 
regulated differently depending on the T cell subsets. In Th1 cells, the 
master regulator of Th1 cells, T-bet, binds to the Icos promoter and 
synergizes with NFATc2 to upregulate ICOS transcription. In Th2 cells, 
NFATc2 also binds to the ICOS promoter, but it is GATA-3 that operates via 
an Icos 3’UTR elements101. This proves relevant as Th2 cells express higher 
levels of ICOS than do Th1 cells83. 
 
1.2.5 B7-H2 (ICOSL or CD275) 
 B7-H2 is a co-stimulatory ligand that only binds ICOS on the T cell 
surface73, 78, 102. B7-H2 is detected on the surface of APCs including B cells, 
DCs, and macrophages and a subset of CD3 T cells, but as well on non-
hematopoietic cells such as endothelial cells and some epithelial cells103, 
104. B7-H2 mRNA is constitutively expressed in several non-hematopoietic 
tissues like the liver, kidney, testes and lung74, 105. Anatomically, B7-H2 is 
expressed in areas where B cell are present like the lymph nodes and the 
spleen76. It was recently discovered that human B7-H2, but not mouse B7-
H2, also binds to CD28 and CTLA-4. Thus, ICOS, CD28 and CTLA-4 may 
compete for a similar binding site on human B7-H2106. The questions 
regarding the physiologic role of the B7-H2 interaction with CD28 and 
CTLA-4 in vivo remain unresolved. 
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1.2.6 Disease relevance 
 ICOS defect in humans has been reported to cause common 
variable immunodeficiency (CVID), a disease characterized by a severe 
reduction in class-switched antibodies, a failure to mount specific 
antibody responses to vaccination or natural infection and 
hypogammaglobulinemia and recurrent bacterial infections93, 107, 108. 
Consistently, mice with ICOS or ICOSL deficiencies also have severe 
defects in Tfh cell generation and GC reactions92, 109-113. On the contrary, 
mice with increased surface expression levels of ICOS have increased Tfh 
cell numbers and are prone to autoimmunity114, 115. ICOS was found highly 
expressed on activated CD4+ T cells in patients with autoimmune 
conditions such as rheumatoid arthritis (RA), systemic lupus erythematosus 
(SLE), and inflammatory bowel disease116-118. ICOS-deficient mice were 
noted to have reduced total IgG and anti-dsDNA production119. ICOS-L 
blockade of a mouse cardiac allograft model was shown to enhance 
cardiac graft survival where CD28 costimulation was absent and while 
CD8 T cells, CTLA-4, and the STAT-6 pathway were functionally active120. 
 Recent studies published in collaboration with our lab showed that 
ICOS plays an important role in inducing acute graft-versus-host disease 
(GVHD) in murine models of allogeneic bone marrow transplant (BMT)121. 
Furthermore, using the ICOS-Y181F mouse strain, we showed that this 
contribution was mediated by PI3K-independent mechanisms122. However, 
the mechanism by which ICOS triggers the onset of the disease remains 
unknown. GVHD is a major complication following allogenic 
hematopoietic stem cell transplantation, in which the grafted cells 
recognizes allogeneic antigens on host tissue cells leading to subsequent 
inflammation and tissue damage. Standard treatments are 1-2 mg/day of 
prednisone with continued administration of calcineurin inhibitor for 
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steroid sparing. However, the general prognosis remains weak123. Several 
players are hinted as being potentially involved in the acute manifestation 
of the disease, with TGF-β124, T regulatory cells (Tregs)125 and Th1/Th2/Th17 
cytokine126-128 having potential roles. It becomes apparent that further 
research on the pathophysiology of GVHD may facilitate the 
establishment of novel strategies leading to prevention and cure of this 
disease. With the promising results observed with ICOS122 and the 
favourable effects of blocking Ca2+ signaling in standard treatments, 
understanding in depth how ICOS-mediated Ca2+ signaling functions 
might prove beneficial in preventing GVHD.  
 
1.3 Calcium signaling pathway in T cells 
1.3.1 General overview 
 A rapid increase in intracellular Ca2+ concentration is crucial for 
T cell activation and modulation of TCR signal intensity129, 130. A remarkable 
variety of Ca2+ signals in T cells, ranging from infrequent spikes to sustained 
oscillations and plateaus, derived from the interactions of multiple Ca2+ 
sources and sinks in the cell. By depleting the stores prolonged Ca2+ influx 
is triggered through calcium release activated calcium channels (CRAC) 
in the plasma membrane. The range and dynamics of Ca2+ signals are 
shaped by the action of several intertwining mechanisms. These different 
events include potassium (K+) channels and membrane potentials, 
mitochondria that buffer Ca2+ preventing the activation of CRAC 
channels and plasma membrane Ca2+-ATPase (PMCA). 
 The initial steps of TCR-mediated calcium signaling are well 
established129. As previously described, upon TCR engagement, SFKs is 
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activated, resulting in the phosphorylation of, amongst other CD3 
modules, the ζ chain of the TCR complex. This leads to the recruitment 
and activation of ZAP70, and then LAT. Tyrosine- phosphorylated LAT then 
recruits several SH2-containing proteins, including PLC-γ1.  
 
1.3.2 PLCγ1 
 Upon activation, PLCγ1 interacts with the phosphorylated 
tyrosine 136 of LAT. Stabilization of this interaction by the adaptors GADS 
(that bind LAT p–Y175 and p-Y195) and SLP-76 allows phosphorylation of 
PLCγ1 on residues critical for its activation37. Once activated, PLCγ1 
cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) to generate two 
distinct secondary messengers: inositol 1,4,5-triphosphate (IP3) and 
diacylglycerol (DAG).  
 DAG activates RasGRP1 by either directly binding its C1 domain 
of RasGRP1 or indirectly by activating novel protein kinase C (PKC) 
isoforms (notably PKCθ). RasGRP1 is phosphorylated at the tyrosine 184 
and its RasGEF activity is increased. PKCθ along with calmodulin 
and calcium/calmodulin-dependent protein kinase-2 (CalmK2) regulates 
the phosphorylation state of the inhibitor of kappa light polypeptide gene 
enhancer in B-Cells (IkB) kinase (IκK) complex through direct and indirect 
interactions. Activated IκK induces phosphorylation and degradation of 
IkB, and nuclear factor-kappaB (NF-κB) can be released from IkB and 
translocate into the nucleus.  
 The other second messenger IP3 travels through the cytoplasm 
and induces the release of intracellular Ca2+ by binding to the IP3 
receptor located on the outer membrane of the endoplasmic reticulum 
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(ER). Ca2+ activates the phosphatase calcineurin, which dephosphorylates 
the transcription factor nuclear factor of activated T cells (NFAT) in the 
cytoplasm. This induces the translocation of NFAT to the nucleus and the 
transcription of a large array of genes such as IL-2 and IFN-γ. The 
relationship between PLCγ1 and ICOS, as well as the role of ICOS-
mediated Ca2+ flux potentiation has yet to be fully examined (depicted in 
Figure 1.2 along with a summary of TCR-mediated Ca2+ signaling, p.20).  
 
CRAC Channels 
 In T lymphocytes, CRAC channels constitute the only pathway for 
Ca2+ entry following TCR engagement. Their function is essentially to drive 
the program of gene expression that underlies T-cell activation by 
antigen.  Prolonged Ca2+ entry through CRAC channels is essential to 
activate transcription factors such as NFAT initiating many of the changes 
in gene expression131. Abrogated signaling through CRAC channels results 
in a lethal severe combined immunodeficiency (SCID) syndrome in 
human patients, characterized by defective T-cell activation and 
proliferation132, 133. Studies have established that CRAC channels are the 
primary Ca2+-influx pathway that is activated upon TCR engagement in T 
cells and their essential role in T-cell function and human health133-135. 
Since the discovery of CRAC channels no mechanism had been 
proposed to explain how their function is regulated. In the last few years, 
the first molecular components of this pathway have been identified. The 
first one is the ER Ca2+ sensor, the stromal interaction molecule 1 (STIM1)136, 
137. The second one is Orai1, a pore-forming subunit of the CRAC 
channel138, 139. Recent work shows that CRAC channels are activated in a 
complex fashion that involves co-clustering of STIM1 in junctional ER near 
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the plasma membrane140, 141. They align to face opposite to Orai1 
molecules. These studies reveal an abundance of sites where 
Ca2+ signaling might be controlled to modulate the activity of T cells 
during the immune response. To balance the concentration of Ca2+ inside 
the cells, PMCAs provide the dominant mechanism though which 
clearance of the ions occurs142, 143. At the beginning of this project, there 
was no information as to where ICOS fits in these general Ca2+ signaling 
pathways in T cells.   
 
Figure 1.2: Overview of Ca2+ signaling pathways in T cells. IP3 releases Ca2+ from the ER. 
Depletion of the intracellular Ca2+ stores activates plasma membrane CRAC channels. 
Ca2+ depletion is detected by Ca2+ sensor STIM1 on the ER membrane. It then associates 
with the CRAC channels (purple dashed line). Ca2+ entering the cell activates the 
K+/Ca2+ channels and upregulates PMCA activity. Calcineurin is activated and it leads to 
dephosphorylation of NFAT allowing its translocation into the nucleus. Mitochondria take 
up Ca2+ near the CRAC channels to prevent their auto-inactivation by negative 
feedback-loop, redistributing it elsewhere in the cell. The route by which ICOS achieves 
its function in mediating Ca2+-flux needs to be investigated (green dashed lines).  
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MATERIALS AND METHODS 
Mice 
C57BL/6 mice (WT) were purchased from Jackson Laboratory (Bar Harbor, 
ME, USA). ICOS-KO (Icos-/-) or ICOS-YF knock-in (Icosyf/yf) mouse strains 
were previously described79, 111. FYN-KO (Fyn-/-) mice were provided by Dr. 
A. Veillette (IRCM, Montreal, QC, Canada) and were previously 
described34, 145. All the mice were in C57BL/6 background (minimum N10) 
and were housed in the IRCM Animal Facility under specific pathogen-
free conditions. Animal experiments were performed according to animal 
use protocols approved by the IRCM Animal Care Committee. 
 
Antibodies and cytokines 
  For T cell stimulation, the following functional grade purified Armenian 
hamster anti-mouse antibodies were used: antibodies against ICOS (mAb 
C398.4A), CD3 (145.2C11) and CD28 (37.51)(eBioscience). For flow 
cytometry, the following Armenian hamster anti-mouse antibodies were 
used: PE-conjugated anti-ICOS (mAb 15F9), biotinylated anti-ICOS (mAb 
C398.4A), biotinylated anti-CD3ε (mAb 145.2C11), biotinylated anti-CD28 
(mAb 37.51)(eBioscience). Goat anti-Armenian hamster IgG (Jackson 
Immunoresearch) or avidin (Calbiochem) were used to crosslink primary 
antibodies. For immunoblots, the following antibodies were used: goat 
anti-mouse ICOS (Santa Cruz, sc-5748), rabbit anti-mouse PLCγ1 (Santa 
Cruz, sc-81), mouse anti-human/mouse GAPDH (Santa Cruz, sc-32233), 
mouse anti-human/mouse pTyr (4G10; Millipore), rabbit anti-mouse pY505-
Lck (Cell Signaling, 2751P), rabbit anti-mouse pY783-PLCγ1 (Cell Signaling, 
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2821S).  HRP-conjugated goat anti-rabbit or sheep anti-mouse secondary 
antibodies were purchased from BioRad. Rabbit antisera against mouse 
Lck, Fyn or ZAP-70 were kind gifts from Dr. A. Veillette (IRCM, Montreal, QC, 
Canada). Recombinant IL-2 was purchased from Peprotech. 
 
Reagents 
The PLCγ1 inhibitor U73122 and its non-specific analog U73343 were from 
Calbiochem. Hexadimethrine bromide (polybrene), sucrose, calcium 
chloride, magnesium chloride, EGTA, Brij58, methylcyclodextrin and n-
Dodecyl β-D-maltoside were purchased from Sigma. Nonidet p-40 was 
purchased from Calbiochem. 
 
In vitro CD4 T cells isolation, activation and restimulation 
CD4 T cells were isolated from splenocytes and superficial lymph nodes 
(popliteal, axillary, inguinal and submandibular) using Mouse CD4 T cell 
Enrichment KitTM (EasySep) according to the manufacturer’s instructions.  T 
cells were cultured in RPMI1640 medium supplemented with 10 % FBS, 300 
mg/ml glutamine, 1 Unit/ml penicillin, 1 µg/ml streptomycin, 55 mM β-
mercaptoethanol and 10 mM HEPES. Purified CD4 T cells were activated 
by culturing with plate-bound anti-CD3 (3 µg/mL) and soluble anti-CD28 
(2 µg/mL) for 2 days and were subsequently expanded in media 
containing 100 U/mL IL-2 (Peprotech) for 3 days. For restimulation 
experiments, CD4 T cell blasts were harvested and incubated for 1 min at 
room temperature with primary antibodies: anti-CD3 (1 µg/mL) alone or 
anti-CD3 (1 µg/mL) plus anti-ICOS (2 µg/mL). Immediately after addition of 
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anti-hamster IgG (20 µg/mL) for crosslinking, the cells were transferred to a 
water bath at 37 °C and incubated for 1–5 min depending on 
experimental settings. 
 
Jurkat cells 
Jurkat, JCam1 (Lck-deficient Jurkat), P116 (ZAP70-deficienct Jurkat), and 
their reconstituted counterpart cell lines were generous gifts from Dr. A. 
Weiss (UCSF, San-Francisco, CA, USA). Jgamma1 (PLCγ1-deficient Jurkat) 
and its reconstituted counterpart cell lines were purchased from ATCC, All 
Jurkat-derived cell lines were cultured according to ATCC guidelines in 
RPMI1640 medium supplemented with 10 % FBS, 300 mg/ml glutamine, 1 
Unit/ml penicillin, 1 µg/ml streptomycin, 55 mM β-mercaptoethanol and 10 
mM HEPES. For reconstituted cell lines P116_WT and Jgamma1_WT 
geneticin (G418) (Sigma) was added (2 mg/ml) to maintain the ectopic 
expression of the reconstituted genes.  The Jurkat-Eco (Jurkat derivative 
expressing ecotropic receptor) cell line was obtained from Dr. Linda Penn 
(OCI, Toronto, Canada).  
 
Ca2+ flux 
For Indo-1 loading, CD4+ T blasts (1 X 107 cells/ml) were incubated for 30 
min with Indo-1 AM (Life Technologies) in Ca2+ buffer (HBSS buffer 
supplemented with 0.1 % BSA, 1 mM CaCl2 and 1 mM MgCl2). After 
washing, cells were stained with anti-ICOS-PE (15F9). For stimulation, Indo-1 
loaded ICOS stained cells (1 X 106 cells in 50 μl) were incubated for 1 min 
at room temperature with biotinylated antibodies: 0.2 μg/ml of anti-CD3 
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+/- 2 μg/ml anti-ICOS. When needed, EGTA was added to the media to 
chelate Ca2+ ions (at a concentration of 2.5 mM).  After diluting in 500 μl 
of total Ca2+ buffer, cells were run in LSR II flow cytometer (BD). After 
recording baseline for 30 sec, avidin (28 µg/ml) was added and the 
mobilization of intracellular Ca2+ was monitored by measuring FL4/FL5 ratio. 
Equal loading of Indo-1 was confirmed by releasing intracellular Ca2+ by 
ionomycin (Sigma-Aldrich, 1 µg/ml). The same procedure was performed 
for Jurkat cells, except that the stimulation was achieved with biotinylated 
anti-ICOS antibody without anti-TCR antibody.  
 
Immunoprecipitation and immunoblot analysis 
Restimulation was stopped by adding ice-cold Ca2+ buffer with 10 % FBS, 1 
mM Na3VO4, 1 mM EDTA pH 8.0. Cells were lysed in NP-40 lysis buffer (1 % 
NP-40 in 10 mM Tris pH 7.5, 5 mM Na4P2O7, 100 µM Na3VO4, 5 mM NaF, 150 
mM NaCl, 1 mM PMSF and protease inhibitor cocktail (Sigma)) or digitonin 
lysis buffer (the same recipe with 1 % Digitonin instead of NP-40) for 20 min 
on ice. Cell debris was removed by centrifugation at 16,000 x g for 10 min 
at 4 °C and the cleared lysates were collected. For immunoprecipitation, 
the cleared lysates were incubated for 1 hour on ice after addition of 
indicated antibodies (2 µg/ml). Immune complexes were recovered with 
protein A beads (Pierce) (1 hour on rocker at 4 C) and then washed in NP-
40 lysis buffer (two times in 1 ml).  Cleared lysates or immunoprecipitates 
were boiled in SDS-PAGE sample buffer. The samples were run on 8 % (for 
PLCγ1) or 12 % (all other proteins) SDS-PAGE gels and transferred to 
Amersham Hyperfilm ECL nitrocellulose membranes (GE Healthcare). 
Blocking was performed in either 5 % fat-free skim milk powder (Lck, ZAP-
70, Fyn and ICOS) or 5 % BSA (PLCγ1, pY783-PLCγ1, pY394-Lck, pY505-Lck, 
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GAPDH), both in TBST. Detection was achieved with Amersham ECL PlusTM 
Western Blotting Detection Reagents (GE Healthcare), membranes were 
revealed using ChemiDocTM MP Imaging System (BioRad) and protein 
bands were quantified using the Image LabTM software (BioRad).  
 
Plasmid construction and cell transfection  
Mutant ICOS constructs were generated by site-directed mutagenesis 
using the GeneArt Site-Directed Mutagenesis System (Invitrogen) 
according to the manufacturer’s instructions with modifications: Platinium 
Pfx® high capacity DNA polymerase (Life technology) was used instead of 
Accuprime Pfx®  and 50mM MgSO4 and 10mM dNTPs were added to the 
PCR mixture for each mutagenesis reaction as normally these 
components are present in the Accuprime Pfx® reaction mix. . Methylation 
of the template DNA was accomplished in a 37°C water bath prior to 
mutagenesis PCR reaction. Primers are detailed in Appendix (Table 1, 
p.67). Template DNA used was pBMN_ICOS_IRES_GFP plasmid. ICOS 
mutant constructs were expressed in ICOS KO CD4 T cells or Jurkat-Eco 
(ICOS negative) cells through retroviral transduction146. In case of Jurkat 
and their derivatives, endofectin-mediated lentiviral transduction method 
was used according to the manufacturer’s instructions to express murine 
ICOS (Ex-Mm07236-Lv81; Genecopoeia). 
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 Sucrose density gradient and lipid raft isolation 
Stimulated cells were lysed in Brij 58 Lysis Buffer (1 % Brij 58, 25 mM Tris [pH 
7.6], 150 mM NaCl, 5 mM EDTA, 1mM Na3VO4, protease/ phosphatase 
inhibitor mix) for 30 min on ice. Lysate was mixed in 1:1 ratio of 80% Sucrose 
(in Brij 58 lysis buffer) and poured in polyallomer centrifuge tubes 
(Beckman Coulter). Column was assembled with subsequent layers of 40 
%, 30 % and 5 % sucrose/lysis buffer. Columns were spun at 39, 000 rpm for 
20 hours with a SW 41 Ti rotor (Beckman Coulter). 1 ml fractions were 
collected and 1 % maltoside was added to each tube to solubilize 
proteins. A portion of the fractions were then boiled with sample buffer 
and analyzed by immunoblot. 
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Chapter 3 
RESULTS 
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RESULTS 
Four membrane proximal residues in the cytoplasmic tail of 
ICOS are sufficient for Ca2+ flux 
 I sought to determine the residues in the cytoplasmic tail of ICOS 
responsible for the potentiation of TCR-mediated Ca2+ release in a PI3K-
independent way.  To this end, I generated a series of ICOS mutants 
through site-directed mutagenesis on ICOS-Y181F backbone cDNA in a 
retroviral vector (pBMN-IRES-GFP). The murine ICOS cytoplasmic tail has 
several evolutionarily conserved regions as shown in Figure 3.1A (p.31). In 
order to delineate the minimal segment of the ICOS tail required for Ca2+ 
flux, I first made truncation mutants by introducing stop codons right after 
Ala185 or Tyr170 (Figure 3.1B, p.31). Once these mutants were generated, I 
expressed them in either Jurkat-Eco cells, which are known to be negative 
for the expression of ICOS88, 147, or in activated primary CD4 T cells isolated 
from ICOS-KO mice. I then tested the ability of these ICOS mutants to 
induce Ca2+ flux. Importantly, I found that ICOS was able to induce Ca2+ 
flux upon ligation without co-ligation with TCR in Jurkat-Eco cells.  This is in 
sharp contrast with CD4 T cells in which ICOS can only potentiate TCR-
mediated Ca2+ flux but cannot function by itself (Figure 3.1C; first panel, 
p.31).  This “autonomous” nature of ICOS-mediated Ca2+ flux in Jurkat-Eco 
cells facilitated biochemical and genetic analyses that can be limited or 
impossible in primary T cells. Through this approach, I found that the 
membrane distal clusters beyond Ala-185 were dispensable for ICOS-
autonomous Ca2+ flux in Jurkat cells as well as potentiation of TCR-
mediated Ca2+ flux in primary CD4 T cells (Figure 3.1C; third panel, p.31). 
Remarkably, when most of the cytoplasmic tail was truncated except the 
four membrane proximal residues, ICOS still maintained its Ca2+ fluxing 
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capacities in both cell types (Figure 3.1C; fourth panel, p.31). Therefore, I 
conclude that the membrane proximal cluster KKKY in the cytoplasmic tail 
of ICOS is sufficient to induce Ca2+ flux. 
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Figure 3.1: Mapping the minimal segment of ICOS cytoplasmic tail sufficient for Ca2+ flux. 
(A) Schematic representation of the transmembrane and cytoplasmic sequence of ICOS 
in multiple species. Evolutionarily conserved regions are highlighted in black. (B) 
Schematic representation of ICOS mutants (C) Autonomous calcium fluxing capacities 
(Jurkat-Eco) or potentiation of TCR-mediated calcium flux by ICOS mutants.  Data shown 
are representative of two independent experiments. 
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The triple lysine motif is necessary for Ca2+ fluxing capacity of 
ICOS 
 To determine whether or not the KKKY motif is essential in mediating 
the Ca2+ fluxing ability of ICOS, I mutated the single tyrosine or the triple 
lysine residues in the ICOS-Y181F context sequence (Figure 3.2A, p.33). 
When the tyrosine at position 170 was mutated to phenylalanine, I 
observed a striking decrease in Ca2+ flux in Jurkat-Eco cells as well as in 
primary CD4 T cells  (Figure 3.2B; second panel, p.33). Similar results were 
obtained when Tyr170 was mutated to alanine (data not shown).  
Mutation of the triple lysine residues  (KKK167-169AAA_Y181F) led to 
substantial reduction of cell surface ICOS level compared to the 
Y170F_Y181F mutant (Figure 3.2C, p.33). In order to overcome these 
differential expression levels, I took a dual staining strategy: a non-agonist 
staining antibody (clone 15F9-PE) to gate on cells expressing similar levels 
of ICOS mutants and an agonist antibody (C398.4A-biotin) to stimulate the 
cells with avidin-mediated crosslinking.  In both cell types, Ca2+ fluxing 
ability of ICOS was completely abrogated when the triple lysine residues 
were changed to alanine (Figure 3.2B; third panel, p.33). I conclude that 
the triple lysine residues are crucial for ICOS-mediated Ca2+ mobilization 
as well as maintaining ICOS on the cell surface. The tyrosine residue at 
position 170 is also involved in Ca2+ mobilization but its contribution to cell 
surface expression of ICOS is minimal.  
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Figure 3.2: Membrane proximal motif KKKY is crucial for ICOS-mediated Ca2+ flux. (A) 
Representation of ICOS tail mutants in the context of full length ICOS-Y181F. (B) Jurkat-Eco 
cells and preactivated ICOS KO CD4 T cells were transduced by retroviral vectors 
encoding indicated ICOS mutant constructs. Both cell types were then examined for 
their ICOS-Ca2+ signaling capacities. (C) Transduced cells were stained with anti-ICOS-PE 
to access surface levels. Data shown are representative of two independent experiments. 
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Interruption of the triple lysine stretch affects Ca2+ flux initiation 
 In order to find ICOS mutants that selectively lose Ca2+ fluxing ability 
without affecting surface expression level, I carried out individual alanine 
mutations of the triple lysine residues in the ICOS-Y181F backbone  (Figure 
3.3A, p.35). These single lysine mutations did not affect the surface 
expression of ICOS on the surface (data not shown). However, the 
mutation of a single lysine residue did not lead to an abrogation of the 
signal. Nonetheless, there were clear delays in the initiation of Ca2+ flux  
(Figure 3.3B, p.35). The delay was biggest when the middle lysine residue 
(K168) was targeted and the impacts of changing the flanking lysine 
residues (K167 or K169) were smaller. These results suggest that an 
uninterrupted stretch of positive charges can be important for ICOS to 
induce Ca2+ flux. It remains to be seen if mutations of the lysine residues for 
a similar stretch of positive residues, such as three arginine residues, would 
occasion the receptor function to become ineffective or keep it intact. 
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Figure 3.3: Single mutations in the membrane proximal triple lysine cluster of ICOS lead to 
delayed Ca2+ initiation. (A) Representation of single lysine ICOS mutants in the context of 
ICOS-Y181F. (B) Jurkat-Eco cells were transduced by retroviral vectors expressing indicated 
ICOS mutants and were examined for their ICOS-Ca2+ signaling capacities.  
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ICOS induces intracellular Ca2+ release from the intracellular 
pool 
 ICOS could be involved in TCR-mediated Ca2+ flux possibly through 
the release of the intracellular pool of Ca2+ from the ER or in the later 
stages by interacting with plasma membrane CRAC channels. I tested if 
ICOS can induce calcium release from the intracellular pool by analyzing 
Ca2+ flux capacities of ICOS-Y181F expressed in Jurkat-Eco cells in the 
presence or absence of Ca2+ chelator ethylene glycol tetraacetic acid 
(EGTA) in the buffer. I observed that despite the deprivation of 
extracellular Ca2+, the initial Ca2+ release peak was maintained (Figure 
3.4A, p.37). Consistent with this, I have preliminary data showing that when 
the cells are treated with U73122, an inhibitor of PLCγ1148, 149, ICOS-
mediated Ca2+ induction is compromised in comparison with treatment 
with U73343, an inactive analog of the inhibitor (Figure 3.4B, p.37). In this 
setting, cell viability was reduced, as the concentration of the inhibitor 
might have been higher than optimal for Jurkat-Eco cells 150.  Although it 
needs to be further substantiated, these results suggest that ICOS is 
involved in the earlier events of intracellular Ca2+ release in T cells possibly 
through PLCγ1.     
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Figure 3.4: ICOS is involved in the release of intracellular Ca2+. Jurkat-Eco ICOS_Y181F cells 
were examined for their ICOS-Ca2+ signaling capacities (A) in the presence of Ca2+ 
chelator EGTA, or (B) after treatment with PLCγ1 inhibitor U73122 or it’s inactive analog 
U73343. Data shown are representative of two independent experiments. 
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Ca2+ flux was completely abrogated (Figure 3.5A, p.39). I then 
investigated the potential involvements of Fyn and Lck in ICOS-mediated 
Ca2+ flux. I tested the fluxing abilities of primary CD4 T cells isolated from 
Fyn-/- mice compared to those from WT littermates. I found that Fyn-
deficient T cells had largely intact ICOS-mediated potentiation of TCR-
mediated Ca2+ flux (Figure 3.5B, p.39). Next, I examined the specific 
contribution of Lck using Lck-deficient Jurkat cell line JCam1 and its 
reconstituted derivative JCam1_Lck151 (Figure 3.5C, p.39).  After expressing 
murine ICOS in these cells through endofectin-mediated lentiviral 
transduction, I analyzed their Ca2+ flux capacities. In these preliminary 
experiments, I observed a total abrogation of Ca2+ flux in JCam1 cells 
whereas JCam1_Lck cell had an intact Ca2+ flux (Figure 3.5D, p.39).  
Based on these, I conclude that ICOS-mediated Ca2+ flux depend on the 
Src family kinase Lck whereas Fyn is dispensable. 
	   39	  
 
Figure 3.5: ICOS mediates its Ca2+ flux function through Src family kinases. (A) Jurkat 
ICOS_Y181F cells were examined for their ICOS-Ca2+ signaling capacities after treatment 
with Src family kinases inhibitor PP2. (B) Preactivated CD4 T cells were prepared from WT 
or Fyn-KO mice and were examined for their ICOS-Ca2+ signaling capacities. (C) Western 
Blot depicting complete loss of specific proteins in respectively depleted Jurkat mutants 
and their reconstituted counterparts. (D) JCam1 and JCam1_Lck cells were given ICOS- 
Y181F expressing plasmids by retroviral transduction and were then examined for their 
ICOS-Ca2+ signaling capacities. Data shown are representative of four independent 
experiments. 
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Following stimulation, ICOS associates with Lck and ZAP70 and 
increases activation of PLCγ1 
 In an effort to understand the mechanism by which ICOS interacts 
with Lck and PLCγ1 during Ca2+ flux potentiation, I performed in-depth 
biochemical analysis of different TCR signaling components following 
stimulation of the cells. I stimulated activated primary WT CD4 T cells with 
anti-CD3 without or with anti-ICOS and prepared cell lysates to analyze 
protein interactions and phosphorylation status. First, to see whether ICOS 
was associated with known TCR proximal kinases, I lysed the stimulated 
cells with a mild detergent digitonin to maximize the recovery of protein 
complexes. After immunoprecipitation of ICOS, I noticed that without 
costimulation the co-receptor was already associated with significant 
levels of Lck and some ZAP-70 molecules (Figure 3.6A, p.41). Remarkably, 
after costimulation the abundance of Lck molecules increased by 60 % 
and ZAP-70 by 80 %. To specifically look at Lck phosphorylation status13, 152, 
I immunoprecipitated Lck directly following lysis in NP-40 lysis buffer. No 
significant differences were detected for either Tyr505 (Lck inhibitory 
tyrosine) or Tyr394 (Lck activating tyrosine)(Figure 3.6A, p.41). Total tyrosine 
phosphorylation (p-Tyr) didn’t show any differences as well ruling out 
potential changes at other sites on the protein. PLCγ1 is known to be 
activated through phosphorylation of Tyr793. By immunoprecipitating 
PLCγ1, I aimed to look at whether or not after stimulation, ICOS 
augmented PLCγ1 activation through the phosphorylation of Tyr793153, 154. 
Strikingly, costimulation of ICOS significantly increased PLCγ1 activation 
compared to TCR stimulation alone (Figure 3.6B, p.41). Thus, ICOS 
associates with Lck and ZAP-70 and increases PLCγ1 activation in the 
context of CD4 T cell costimulation. 
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Figure 3.6: ICOS associates with Lck and ZAP-70 and increases PLCγ1 activation. (A) 
Western Blot revealing the effect of ICOS costimulation on the association of Src family 
kinases with ICOS and changes in their activation status. (B) Western Blot portraying 
changes in PLCγ1 phosphorylation status upon ICOS costimulation. 
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was present in those lipid rafts and that Lck was recruited to the area 
upon T cell stimulation34, 157, 158. I wanted to determine whether ICOS 
needed to relocalize into lipid rafts in order to carry out its Ca2+ flux 
functions. As a preliminary experiment, I first examined the effects of 
disrupting the lipid rafts by treating the cells with different doses of methyl-
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β-cyclodextrin (MCD), a compound forming inclusion complexes with 
cholesterol, therefore disrupting the lipid rafts159. The ability of ICOS-Y181F 
expressing Jurkat-Eco cells to induce Ca2+ flux through ICOS was 
significantly compromised by MCD in a dose-dependent manner (Figure 
3.7A, p.43). Next I tried to determine if ICOS was indeed relocalizing into 
the membrane lipid rafts. For this purpose I isolated lipid rafts by sucrose 
density from Jurkat-Eco cells expressing ICOS-Y181F following stimulation to 
trigger autonomous Ca2+ flux induction. The fractionation method was first 
confirmed in unstimulated cells by blotting the different fractions of the 
gradient for Fyn, which is known to be mostly present in lipid rafts157, 
160(Figure 3.7B, p.43). Then, following ICOS stimulation, I isolated and 
pooled the raft-containing fractions along with the soluble fractions and 
blotted each of them for the presence of ICOS, to judge whether or not 
ICOS relocalized after stimulation. I observed no relocalization of ICOS into 
lipid rafts after stimulation (Figure 3.7C, p.43). Therefore, I found no 
evidence that ICOS relocalizes into lipid rafts upon ligation and the 
impact of MCD on ICOS-mediated Ca2+ flux is probably due to a general 
toxic effect caused by disturbance in membrane structure. 
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Figure 3.7: ICOS doesn’t relocalize into lipid rafts upon stimulation  (A) Jurkat ICOS_Y181F 
cells were examined for their ICOS-Ca2+ signaling capacities after treatment with the 
indicated doses of methyl-β-cyclodextrin (MCD). (B) Jurkat ICOS_Y181F cell lysate was 
fractionated by ultracentrifugation on a sucrose gradient. Collected fractions were then 
analyzed by Western Blot to confirm isolation of lipid raft fractionations. (C) Jurkat 
ICOS_Y181F cells were stimulated with α-ICOS, lysed and fractions representing lipid rafts 
and soluble fractions were pooled.  ICOS was immunoprecipitated from these pools and 
the IP products were quantified by Western blot.   
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Chapter 4 
DISCUSSION & SUMMARY 
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DISCUSSION  
 As discussed in the opening chapter, ICOS potentiates TCR-
mediated PI3K activation and intracellular calcium mobilization. Our 
group previously showed that the ICOS-Y181F mutation selectively 
abrogated the capacity of ICOS to recruit PI3K but still led to TCR-
mediated Ca2+ flux potentiation79.  In collaboration with Dr. Yu’s group, we 
also demonstrated that ICOS plays an important role in inducing acute 
GVHD in murine models through PI3K-independent manner121 122. However, 
at this point, the ICOS signal transduction pathway(s) involved in GVHD 
remain unknown.  We hypothesized that the intact pathogenic capacity 
of ICOS-Y181F T cells to induce GVHD relies on ICOS-mediated calcium 
signaling. Our initial goals were to identify the residue(s) responsible for this 
ICOS-mediated Ca2+ signaling and find the mechanism by which the 
receptor achieves this function. Through site-directed mutagenesis and 
flow cytometric analysis of calcium fluxing capacities of mutant ICOS 
proteins, I sought to identify the cytoplasmic residues essential for ICOS-
mediated Ca2+ signaling. 
 In the early stages of this study, I realized that ICOS, when 
transduced in Jurkat-Eco cells, enacted its Ca2+ flux function 
independently of TCR co-ligation. In primary CD4 T cells, this feature 
remained unachievable as ICOS depends on TCR stimulation. The 
“autonomous” nature of ICOS-mediated Ca2+ flux in Jurkat-Eco cells 
facilitated biochemical and genetic analyses that can be either limited or 
impossible in primary T cells.  Specifically, targeted disruption of genes 
encoding Lck, ZAP-70, or PLCγ1 in mice leads to defects in T cell 
development161, 162.  However, Jurkat mutants lacking these components 
proved to be viable with defects in TCR signaling.  163-165. It is important to 
note that every time a mutant form of ICOS was expressed in either system 
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(Jurkat or primary CD4+ T cells), Ca2+ flux patterns were congruent 
suggesting these two systems use the same biochemical signaling 
mechanisms. Also, all the mutants tested never displayed an ICOS 
autonomous Ca2+ flux phenotype in primary CD4+ T cells. Although the 
lack of autonomous Ca2+ fluxing capacity by ICOS in primary T cells 
presumably prevent inappropriate activation of autoreactive T cells, it 
remains elusive how this can be achieved at molecular level.  In primary T 
cells, ICOS could be repressed until initial TCR-mediated signal(s) lift the 
repression mechanism. In Jurkat cells, ICOS could be circumventing the 
initial requirements to lift this repression due to the increase amount of Itk 
and its chronically elevated activity166. Indeed, Itk is known to interact with 
Fyn in the early stages of TCR signaling167. It is possible that the 
abundance of Itk could lead to a bypass of TCR-mediated ICOS licensing, 
allowing it to directly potentiate, or in this case induce, Ca2+ flux. It is still 
unclear if ICOS directly utilizes the TCR machinery in Jurkat-Eco cells or if it 
uses an alternative mechanism. One simple way to investigate this 
hypothesis would be by looking at Ca2+ flux capacity of ICOS in Jurkat 
cells lacking the TCR ζ chain. It should help us unfold the reasons behind 
ICOS autonomous Ca2+ flux induction in Jurkat cells. 
 For the identification of the cytoplasmic cluster(s) of residues 
essential in inducing ICOS-mediated Ca2+ signaling, I examined the 
evolutionary conserved clusters in the cytoplasmic tail of ICOS. ICOS 
possesses three conserved clusters in its cytoplasmic tail: the KKKY cluster 
spanning positions 167 to 170, the SVHDPN from positions 173 to 178 and 
the AVNTNKK cluster from positions 186 to 192. Triple lysine motifs have 
been documented as having various applications for different protein 
functions. One of them is for extracellular matrix adhesion by peripheral 
blood T cells with cyclophilins (cyclosporine A-binding proteins)168 that 
contain the KKK motif as a binding site for glycosaminoglycans (GAGs). In 
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this protein, the lys-lys-lys cluster forms a binding site for GAGs in 
association with another cluster in the protein’s sequence169. A triple lysine 
cluster also represents a positively charged binding site. Negatively 
charged triple glutamic acid clusters (EEE) are known binding sites present 
in calmodulin170, 171. Common posttranslational modifications of lysine, e.g. 
methylation of the ε-amino group NH3+, as it occurs in calmodulin, allows 
for participation in hydrogen bonding and as a general base in catalysis. 
The co-receptor CTLA-4, also bears a lysine rich motif essential to interact 
with the enzyme PP2A172-174. PP2A is essential to control cell signaling by 
timely inactivation of kinase signaling cascades. Although there is no 
evidence for direct binding of PP2A and calmodulin to ICOS in our mass-
spectrometry-based screening experiments these examples of Lys cluster 
in protein-protein interaction suggest its role in signal transduction.  The 
second conserved cluster SVHDPN contains a SXXD motif that is a well 
known consensus phosphorylation site for the serine/threonine selective 
protein kinase Casein kinase 2 (CK2)175. CK2 is a pleiotropic protein kinase 
known to be targeting several different substrates176. CK2 is notably 
implicated in cell signaling and proliferation177, 178. CK2 is already 
recognized as being implicated in Ca2+ signaling in T cells through 
association with CD45179. The D2 domain of CD45 contains four CK2 
phosphorylation sites and is implicated in the regulation of the 
calcium/NFAT T cell activation pathway180. And finally, TXK motifs are 
consensus phosphorylation sites for protein kinase C (PKC). PKC are 
activated by increases of DAG and Ca2+181. PKC activation leads to 
downstream NFAT and NFκB activation182. These three key consensus sites 
present in the cytoplasmic tail sequence of ICOS possibly relate to 
signaling molecules closely or remotely involved in the signaling pathways 
downstream of TCR triggering. I predicted that the key-signaling motif of 
ICOS-mediated Ca2+ flux to be one of these three clusters. My data 
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indicated that the ICOS mutants targeting the SVHDPN and AVNTNKK 
conserved regions still maintaining ICOS Ca2+ flux abilities (data not 
shown; primer sequences in Table 1; -Appendix Table 1, p.67). Results from 
truncated ICOS mutants  (A185-Stop, Y170-Stop) are consistent with these 
data (depicted in Figure1C, p.31). The data from Y170-Stop mutant 
indicate that the membrane proximal KKKY region is sufficient for ICOS-
mediated Ca2+ flux.  Furthermore, mutating the KKKY region to alanine 
residues in the full-length context led to total abrogation of the Ca2+ 
fluxing capacities of ICOS, an effect not observed for the other conserved 
clusters of the cytoplasmic tail. Therefore, I identified a membrane 
proximal cluster of lysine residues both sufficient and necessary for ICOS-
mediated Ca2+ flux.  
Importantly, this KKK cluster is also important to maintain ICOS on 
the T cell surface as triple Ala mutation drastically reduces cell surface 
ICOS level.  This dual function of KKK cluster was not easily separable.  
However, the fact that single Ala mutation can delay Ca2+ flux with 
minimal impact on cell surface levels imply that mediators of Ca2+ flux 
may rely on the triple lysine residues more heavily than those involved in 
ensuring ICOS on the cell surface.  It remains as a challenge to identify a 
mutant ICOS that selective loses the ability to flux Ca2+ while maintaining 
normal ICOS surface level.  A systematic combinatorial mutagenesis 
approach in which two residues of the three lysine residues in the KKK 
cluster are replaced by alanine or glutamic acid residues may prove 
fruitful.     
 It is puzzling how ICOS is licensed by TCR signaling to potentiate 
Ca2+ flux in primary T cells.  One tempting hypothesis is that the highly 
positive KKK cluster of the cytoplasmic tail of ICOS is normally bound to the 
negatively charged membrane through ionic interactions preventing its 
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function, a phenomenon reported for TCR CD3 chains183. A local influx of 
Ca2+ near the TCR may release ICOS tails from the membrane so that it 
can activate downstream signaling cascade.  To test this, I added 
strontium ions (Sr2+) in the buffer used to carry out our Ca2+ flux 
experiments. I proceeded with Ca2+ flux analysis of primary WT CD4 T cells 
treated with that modified buffer (Figure S1; Appendix, p.68). Under these 
conditions, ICOS was still unable to achieve autonomous ICOS-mediated 
Ca2+ flux in primary cells. Thus, it remains to be seen what is mediating the 
repression of ICOS-Ca2+ pathway in the absence of TCR signaling in 
primary T cells. Another tantalizing hypothesis would be that mechanism 
mediating ICOS licensing would be the same mechanism observed for the 
lysine rich motif in CTLA-4. In the case of CTLA-4, the key signaling kinases 
involved downstream are binding this lysine repeat site leading to 
modifications of the phosphorylation state of a tyrosine residue located 
upstream of its the cytoplasmic tail172-174.  In ICOS, a tyrosine residue 
follows the lysine rich repeat. It is fair to suggest that this tyrosine residue 
could be involved in TCR-mediated ICOS licensing. 
 I provided preliminary evidence for the involvement of the Src 
family kinase Lck as the potential key signaling molecule downstream of 
the initial events triggering ICOS-mediated Ca2+ flux. Jurkat mutants 
lacking Lck (JCam1) were unable to induce Ca2+ flux by ICOS stimulation 
while their reconstituted counterparts were (JCam1_Lck). Jurkat mutant 
experiments need to be revisited as the preliminary ones involving 
lentivirus-mediated transduction of Jurkat cells led to reduced cell viability. 
This made impossible the rendition of analysis through kinetics as too few 
cells were responding to the signals. A new approach through 
electroporation gave better results and should be able to provide 
conclusive data. Supplemental experiments were performed to further 
demonstrate the crucial role of Lck in this process. Lck is known to be 
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constitutively active in T cells and its maintenance relies on the HSP90-
CDC37 chaperone complex23, 184, 185. Tanespimycin (17-AAG) is an analog 
of geldanamycin, a proven HSP90 inhibitor186, 187. I treated the cells with 
this compound in order to test the effects on ICOS-mediated Ca2+ flux. In 
my experimental settings, the compound’s efficiency wasn’t optimal, but 
even with ~30% reduction of activated Lck I still observed a delay in Ca2+ 
flux initiation (Figure S2; Appendix, p.68). Altogether, these data strongly 
correlate in showing that Lck is crucial in carrying out ICOS signal 
downstream to mediated Ca2+ flux induction.  I also found no evidence 
that ICOS relocalizes into lipid rafts upon ligation. Therefore the potential 
interaction with Lck is probably not occurring in lipid rafts. Next aim is to 
define signaling components downstream of Lck.  A logical extension is to 
perform Ca2+ flux assays using Jurkat mutants lacking ZAP-70 and PLCγ1. I 
predict the outcome to be consistent with the results obtained from Lck-
mutant Jurkat cells. 
 I showed that ICOS stimulation led to the elevated activation of 
PLCγ1 and that the release of Ca2+ originated from the intracellular pool. 
Whether it is directly involved in the release from the ER through the IP3 
receptor remains to be proven. Another possibility is that it could involve 
mitochondria since they are known to be involved in Ca2+ signaling188, but 
since their involvement concerns the regulation of CRAC channels rather 
than the release from the ER, it is unlikely that ICOS governs their 
activation. The results on PLCγ1 activation were shown in an ICOS-WT 
context. The next step is to confirm it in an ICOS-Y181F context and 
determine if mutations that affect Ca2+ flux also compromise or disrupt Lck 
association and PLCγ1 activation. 
 I still don’t know what role ICOS might play downstream of PLCγ1. 
Downstream of the Ca2+ signaling pathway, NFAT is relocalized to the 
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nucleus after activation. The activation of AKT by PI3K can lead to an 
inhibition of the GSK3β kinase189, 190. In the recent years, GSK3β has been 
showed to mediate NFAT phosphorylation in the nucleus leading to its 
nuclear export and therefore, its inactivation191. This allows the cell to 
dictate the occupancy time of transcription factors inside the nucleus192. 
Although, we have shown that ICOS-PI3K pathway is dispensable for early 
Ca2+ flux, where we measure the release of Ca2+ from the intracellular 
pool, later signaling events might require the involvement of PI3K. This can 
be relevant to distinct behavior of CD4 vs. CD8 T cell subsets in GVHD122. 
Whereas CD8 T cells can induce GVHD independently of ICOS-PI3K 
pathway, CD4 T cells seem dependent on PI3K to set off the disease 
symptoms. One possible explanation can be that in CD4 T cells, NFAT 
nuclear retention could be achieved through PI3K-mediated GSK3β 
suppression. Thus, in the absence of ICOS-PI3K activation pathway, ICOS 
can induce initial Ca2+ flux but NFAT may not be able to stay in the 
nucleus long enough due to insufficient suppression of NFAT export 
mechanism.  In this scenario, CD8 T cells may not need to operate ICOS-
PI3K pathway to maintain NFAT nuclear residence.  It is interesting to see if 
CD8 T cells rely on other kinases such as DYRK1A and DYRK2 rather than 
GSK3β to achieve NFAT nuclear export193.  
 To fully understand the dynamics of costimulation in TCR-mediated 
Ca2+ flux, one cannot underestimate to highly probable involvement of 
CD28194. I have preliminary data showing that ICOS and CD28 act 
synergistically to further potentiate TCR-mediated Ca2+ flux (Figure S3; 
Appendix, p.69). Since the concentrations of anti-ICOS Ab I used in these 
experiments are already saturated, this synergy between ICOS and CD28, 
which goes beyond each receptor’s costimulatory capacities, might 
indicate that the two costimulatory molecules activate distinct pathways 
to accomplish their functions.  Further work is required to test this idea and 
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understand the potential collaboration of these to costimulatory receptors 
in T cell biology. 
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SUMMARY 
  
While most studies involving ICOS in GVHD have confirmed its 
critical role in the disease onset, it is yet to be described how it works.  
 
During the course of my Master’s study, I identified the membrane 
proximal cluster of lysine residues as essential in inducing ICOS-mediated 
Ca2+ signaling. Furthermore, I provided evidence for the involvement of 
the Src family kinase Lck in ICOS-mediated Ca2+signaling. With the added 
insight of preliminary results, I propose a model in which ICOS utilizes Lck-
ZAP70-PLCγ1 signaling axis to potentiate TCR-mediated Ca2+ flux and 
possibly PI3K-independent pathogenic function of T cells in GVHD.   
 
Thus, my study is beginning to unravel a complexity in ICOS-induced 
calcium signaling. Further understanding of this pathway could prove 
beneficial in designing new strategies to prevent ICOS-related diseases 
such as GVHD.  
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Table 1: List of primers used for site-directed mutagenesis  
A185-Stop TTCATGTTCATGGCGTAATAGGCAGTCAACACAAAC 
Y170-Stop TCAAAAAAGAAATACTAATGAGGATCCAGTGTGCAT 
Y170F_Y181F TTTTCAAAAAAGAAATTCGGATCCAGTGTGCAT 
KKK167-169AAA 
_Y181F 
ATCATCTGGTTTTCAGCGGCGGCGTACGGATCCAGTGTG 
K167A_Y181F ATCATCTGGTTTTCAGCAAAGAAATACGGATAA 
K168A_Y181F ATCTGGTTTTCAAAAGCAAAATACTAATGAGGA 
K169A_Y181F TGGTTTTCAAAAAAGGCATACTAATGAGGATCC 
K167A_ K168A 
_Y181F 
ATCATCTGGTTTTCAGCAGCAAAATACGGATCCAGTGTG 
K167A_ K169A 
_Y181F 
ATCATCTGGTTTTCAGCAAAGGCATACGGATCCAGTGTG 
K168A_ K169A 
_Y181F 
ATCATCTGGTTTTCAAAAGCAGCATACGGATCCAGTGTG 
K167E_ K168E 
_Y181F 
ATCATCTGGTTTTCAGAAGAAAAATACGGATCCAGTGTG 
K167E_ K169E 
_Y181F 
ATCATCTGGTTTTCAGAAAAGGAATACGGATCCAGTGTG 
K168E_ K169E 
_Y181F 
ATCATCTGGTTTTCAAAAGAAGAATACGGATCCAGTGTG 
DPN176-178AAA 
_Y181F 
GGATCCAGTGTGCATGCAGCAGCGAGTGAATTCATGTTC 
S173A_ DPN176-
178AAA _Y181F 
AAGAAATACGGATCCGCAGTGCATGCAGCAGCG 
T189A_Y181F ATGGCGGCAGTCAACGCAAACAAAAAGTCTAGA 
K191A_ K192A 
_Y181F 
GCAGTCAACACAAACGCAGCATCTAGACTTGCAGGT 
IWF163-165VAL 
_Y181F 
GGATGCATACTTATCGTGGCGCTGTCAAAAAAGAAATAC 
Sense primer sequences are listed (5’-3’). Orange–highlighted bases represent the 
mutation in the target sequence.  
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Figure S1: Addition of Sr2+ is not sufficient to allow autonomous ICOS-mediated Ca2+ flux in 
primary CD4+ T cells. Preactivated CD4 T cells were prepared from WT mice and were 
then examined for their autonomous ICOS-Ca2+ signaling capacities after addition of Sr2+ 
in the media during Indo-1 loading and stimulation processes. 
 
 
 
 
  
Figure S2: Inhibition of HSP90 by Tanespimycin treatment leads to delayed ICOS-
mediated Ca2+ flux initiation. (A) Western Blot illustrating the effect of 17-AAG on the 
phosphorylation status of Lck after a 3-hour treatment on Jurkat ICOS-Y181F cells. (B) Cells 
were examined for their ICOS-Ca2+ signaling capacities with or without a 17-AGG 
treatment. 
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Figure S3: ICOS and CD28 act synergistically to further potentiate TCR-mediated Ca2+ flux. 
Preactivated CD4 T cells were prepared from WT mice and were examined for their TCR-
Ca2+ signaling capacities in combination with costimulatory signals coming from either 
ICOS and CD28 or both. 
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